Senior Advisors
The leadership team is supported by senior scientific and strategic advisors, including:
Chris is an accomplished physician-scientist with over 30 years of leadership in global drug development. He joined Liminal Biosciences as Acting Chief Medical Officer in April 2025, bringing extensive expertise in translational medicine, clinical pharmacology, and early-phase development.
At Liminal, Chris supports clinical strategy and development across a pipeline of small molecules, targeting metabolic, inflammatory and fibrotic diseases. He has held senior R&D positions at Pfizer, Amgen, Serono, and Dainippon Sumitomo Pharma, and has led numerous first-in-human and early-phase programs across multiple therapeutic areas, including immunology, neuroscience, nephrology, and metabolic disorders.
Chris has worked across more than 20 indications, with particular focus on biomarker-driven development, precision medicine, and the integration of translational tools such as neuroimaging and mechanistic endpoints. He has significant experience in dose selection, risk mitigation, and pediatric development planning.
He has supported global regulatory submissions and agency interactions in the US, EU, Japan, Korea, and China, including INDs, CTAs, NDAs/BLAs, and MAAs. His proven regulatory and clinical development expertise strengthens Liminal’s ability to advance differentiated assets with speed, rigor, and strategic clarity.
Chris plays a key role in accelerating Liminal’s mission to deliver transformative therapies for patients with serious and underserved conditions.
Nick is a highly experienced regulatory compliance specialist and quality manager with over 25 years of expertise in the biopharmaceutical industry. His extensive career encompasses leadership roles in quality assurance across GLP, GCP, and GMP environments, focusing on clinical and pre-clinical audits, quality management systems, SOP development, staff training, and inspection preparation. Nick’s broad experience spans working with pharmaceutical companies, CROs, government research facilities, and biotech firms globally.
Since January 2025, Nick has been serving as Consultant Quality Director at Liminal, where he provides strategic quality leadership, regulatory guidance, and compliance oversight to support the company’s clinical development programs. In this role, he leverages his deep knowledge of global regulations and quality standards to ensure Liminal’s operational excellence and successful regulatory outcomes.
Throughout his career, Nick has managed quality systems for a wide range of biopharma companies, supported first-time clinical trial sponsors, and contributed to successful regulatory inspections with zero critical findings. His pragmatic approach to quality and extensive regulatory expertise make him a trusted advisor in the field.
Mike is a seasoned pharmaceutical executive with over 30 years’ experience in business development, investor relations, and strategic growth within both large pharma and biotech sectors. With a robust scientific background in immunology, CNS, and virology, he specializes in translating scientific innovation into commercially successful partnerships and investment opportunities.
In April 2025, Mike commenced his role as Consultant Business Development Director at Liminal, where he focuses on advancing strategic partnerships, enhancing investor relations, and leading deal negotiations to support the company’s growth and strengthen its position in the competitive pharmaceutical market.
Throughout his career, Mike has led fundraising initiatives exceeding €120 million and managed complex due diligence processes for product acquisitions, divestments, and M&A transactions. At Roche, he played a pivotal role in refocusing the Business Development unit, completing 85 licensing deals over four years and closing over 30 major deals valued at more than $2.3 billion.
He possesses extensive experience in engaging with investors, delivering presentations to Boards of Directors, and chairing senior governance committees to ensure alignment of portfolio strategies with corporate objectives. Mike is highly skilled in cultivating robust investor relations and fostering strategic collaborations that optimize value creation for all stakeholders.